论文部分内容阅读
目的评估新一代质子泵抑制剂雷贝拉唑治疗十二指肠溃疡的疗效。方法确诊为十二指肠溃疡 HP(+)60例分为雷贝拉唑组(RAC组)予雷贝拉唑10mg Qd×4周,联合阿莫西林1g Bid×1周、克拉霉素 500mg Bid×1周;法莫替丁组(FAC组)予法莫替丁20mg Bid×4周,联合阿莫西林1g Bid×1周、克拉霉素 500mg Bid×1周。观察治疗过程中症状改善情况。疗程结束后评价症状改善程度,内镜表现,HP根除情况。结果 RAC组回访27例。FAC组回访29例,1例因治疗过程中出现白细胞降低,转氨酶轻度升高,自动退出观察, 视为失访。两组间治疗前、后(即疗程第28天时)各项症状积分无显著性差异。但RAC组疗程第1、3、6天时各项症状积分下降明显,两组间有显著性差异,溃疡愈合率(RAC组89.6%,FAC组64.3%)及HP根除率(RAC组 80.3%,FAC组61.1%)两组间有显著性差异。结论新一代质子泵抑制剂雷贝拉唑治疗十二指肠溃疡的疗效明显优于H2受体拮抗剂法莫替丁。
Objective To evaluate the efficacy of a new generation of proton pump inhibitor rabeprazole in the treatment of duodenal ulcer. Methods Sixty cases of duodenal ulcer diagnosed as HP (+) were divided into rabeprazole group (RAC group), rabeprazole 10mg Qd × 4 weeks, combined with amoxicillin 1g Bid × 1 week, clarithromycin 500mg Bid × 1 week; famotidine group (FAC group) given famotidine 20 mg Bid × 4 weeks, combined with amoxicillin 1g Bid × 1 week, clarithromycin 500mg Bid × 1 week. Observe the symptoms during the course of treatment. After the end of treatment evaluation of symptoms improvement, endoscopic performance, HP eradication. Results There were 27 cases in the RAC group. In the FAC group, 29 cases were retrospectively reviewed. One patient lost leukopenia due to the course of treatment and the aminotransferase slightly increased. Between the two groups before and after treatment (that is, the 28th day of treatment) symptom scores were not significantly different. However, the symptom score decreased significantly on the 1st, 3rd and 6th day in the RAC group, with significant difference between the two groups. The healing rate of ulcer (89.6% in RAC group and 64.3% in FAC group) and HP eradication rate (80.3% 61.1% in the FAC group) were significantly different between the two groups. Conclusion The new generation of proton pump inhibitor rabeprazole treatment of duodenal ulcer was significantly better than the H2 receptor antagonist famotidine.